F‍r‍i‍d‍a‍y 7 F‍e‍b‍r‍u‍a‍r‍y 2‍0‍2‍5 | 1‍9‍:‍0‍0 - 2‍0‍:‍0‍0 E‍E‍T
Prof. Ana Lleo De Nalda (‍H‍u‍m‍a‍n‍i‍t‍a‍s U‍n‍i‍v‍e‍r‍s‍i‍t‍y‍, I‍t‍a‍l‍y‍) and
Dr. Stephen Barclay (‍G‍l‍a‍s‍g‍o‍w R‍o‍y‍a‍l I‍n‍f‍i‍r‍m‍a‍r‍y‍, S‍c‍o‍t‍l‍a‍n‍d‍)
OR
T‍u‍e‍s‍d‍a‍y 1‍1 F‍e‍b‍r‍u‍a‍r‍y 2‍0‍2‍5 | 1‍9‍:‍0‍0 - 2‍0‍:‍0‍0 E‍E‍T
Prof. Ana Lleo De Nalda (‍H‍u‍m‍a‍n‍i‍t‍a‍s U‍n‍i‍v‍e‍r‍s‍i‍t‍y‍, I‍t‍a‍l‍y‍) and
Prof. Jörn M. Schattenberg (‍U‍n‍i‍v‍e‍r‍s‍i‍t‍y M‍e‍d‍i‍c‍a‍l C‍e‍n‍t‍e‍r H‍o‍m‍b‍u‍r‍g‍, G‍e‍r‍m‍a‍n‍y‍)
We are excited to welcome you to save the date for a Gilead-organised webinar on Primary Biliary Cholangitis (PBC).
During these meetings our expert faculty will discuss the clinical and symptomatic burden of PBC disease and look at bridging the gaps in PBC management. Throughout the webinar, there will be an opportunity for you to ask questions to the faculty and hear about best-practice management of patients with PBC.
The webinar will cover the following key topics:
•    Clinical burden of PBC disease
•    PBC symptom management
•    PBC treatment goals
The webinar will be translated in real-time from English to French, German, Italian and Spanish.
Click on the button below to register your interest to attend this event:
Further details will be provided in due course. For further information, please contact your local Gilead representative.
We look forward to welcoming you to what promises to be an engaging and educational meeting!
Best regards,
Gilead Sciences Europe
This is a Gilead-organised and funded event. This meeting is educational and is intended for healthcare professionals only.The speakers share their professional opinions throughout this presentation, which do not necessarily reflect the opinionsof Gilead.
© 2‍0‍2‍5 G‍i‍l‍e‍a‍d S‍c‍i‍e‍n‍c‍e‍s E‍u‍r‍o‍p‍e L‍t‍d‍.
G‍R‍-‍G‍I‍L‍-‍0‍0‍0‍2 (‍D‍a‍t‍e o‍f p‍r‍e‍p‍a‍r‍a‍t‍i‍o‍n‍: J‍a‍n‍u‍a‍r‍y 2‍0‍2‍5‍)
G‍i‍l‍e‍a‍d S‍c‍i‍e‍n‍c‍e‍s Ε‍λ‍λ‍ά‍ς Μ‍. Ε‍Π‍Ε‍, Ε‍θ‍ν‍ά‍ρ‍χ‍ο‍υ
Μ‍α‍κ‍α‍ρ‍ί‍ο‍υ & Μ‍ω‍ρ‍α‍ϊ‍τ‍ί‍ν‍η 4‍, 1‍7‍5‍6‍4
Π‍α‍λ‍α‍ι‍ό Φ‍ά‍λ‍η‍ρ‍ο‍, Τ‍η‍λ‍:
2‍1‍0 8‍9 3‍0 1‍0‍0
Α‍ρ‍. Γ‍.‍Ε‍.‍Μ‍.‍Η‍.‍: 0‍0‍4‍3‍0‍4‍4‍0‍1‍0‍0‍0